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Available online 8 April 2016Objectives: High-resolution prostate imaging may allow for detection of subtle changes in tumor size, decrease
the reliance on biopsies, and help deﬁne tumor boundaries during ablation. This pilot clinical trial evaluates a
novel high-resolution prostate MRI for detection of small, biopsy-proven prostate tumors.
Methods: Our team developed a software that can be loaded on any modern MRI to generate high resolution
diffusion-weighted imaging sequences (HR-DWI), which were compared to standard diffusion-weighted imag-
ing sequence (S-DWI) in a prospective pilot trial in active surveillance patients. HR-DWI captures the entire vol-
ume of the prostate rather than sections, reducing streaking artifacts and geometric distortions. Multiple shots,
rather than single shots, are used to differentiate signal and noise, enhancing resolution. All images were read
by two radiologists. The primary outcome was the percent of biopsy-proven zones seen in 17 patients. The
trial was powered to detect discordant proportions of 0.04 and 0.40 at one-sided alpha = 0.05.
Results: The resolutionwas deﬁned using standard phantoms. HR-DWI produced a 5-fold improvement in spatial
resolution when compared to S-DWI. Multiparametric (MP)-MRI incorporating S-DWI was useful for predicting
biopsy results (AUC 0.72, Fisher's exact p b 0.001); however, using HR-DWI allowed MP-MRI to be more highly
predictive of biopsy results (AUC 0.88, Fisher's exact p b 0.001). AUC for MP-MRI incorporating HR-DWIwas sig-
niﬁcantly larger thanMP-MRI incorporating S-DWI (p=0.002). MP-MRI with HR-DWI had a sensitivity of 95.7%
and identiﬁed tumor in 22 of 23 zones proven to have cancer on biopsy. In contrast, MP-MRI with S-DWI had a
sensitivity of 60.9% and only identiﬁed 14 of 23 biopsy-positive zones (p = 0.004).
Conclusion:Wedeveloped a novelDWI and evaluated its improved resolution in a clinical setting. This technology
has many potential applications and should be evaluated in future clinical trials as a patient management tool.




Diffusion weighted imaging1. Introduction
Transrectal ultrasound-guided (TRUS) biopsy is the gold standard
for diagnosing prostate cancer and an integral part of cancermonitoring
during active surveillance (AS) (Chen et al., 2016; Mohler et al., 2016).
However, the standard prostate biopsy may miss clinically signiﬁcant
disease (Cohen et al., 2008; Kawachi et al., 2010). Furthermore, TRUS bi-
opsy is accompanied by complications such as systemic infection, bleed-
ing, and transient erectile dysfunction (Loeb et al., 2013). There is a clearresolution diffusion weighted
g; MP-MRI, multiparametric
coefﬁcient; TRUS, transrectal
r, Department of Urology, 8635
8, United States.
. This is an open access article underneed for diagnostic strategies to reduce the clinical burden of diagnos-
ing and monitoring prostate cancer. Better imaging may reduce the re-
liance on biopsies and open but additional therapeutic possibilities.
MultiparametricMRI is commonly employed for detection and local-
ization of prostate cancer (Lawrence et al., 2012; Outwater and
Montilla-Soler, 2013). Unfortunately modern MRI suffers from two im-
portant limitations. Standard MRI captures periodic slices of tissue and
relies on volume averaging, which produces streaking artifacts and geo-
metric distortions. Furthermore, the signal-to-noise ratio on standard
MRI limits spatial resolution. To overcome these limitations, we devel-
oped a modiﬁed three-dimensional, multishot diffusion-weighted im-
aging sequence (HR-DWI) and applied it in a pilot clinical study. The
volumetric imaging improves image quality. Taking multiple shots al-
lows differentiation of signal and noise, further improving resolution.
We choose to test this technology in AS patients who often have low
volume disease, which is very often below the limits of detection bythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to enhance the detection and characterization of prostate cancer, the
long-termnatural history of small prostate cancers not seen on standard
MRI has not been deﬁned. The ﬁrst step in understanding their biology
in an era of molecular diagnostics and next-generation sequencing is to
develop technology to image these lesions. Better imaging will allow
these lesions to bemonitored serially and targeted for biopsy or therapy
(Hu et al., 2014). Improved imaging resolutionwill allow formore accu-
ratemeasurement of size and boundaries, and detection of small chang-
es in size over time.
Our HR-DWI confers a 5-fold improvement in resolutionwhen com-
pared to standard DWI (S-DWI). The goal of this study is to describe our
new imaging system and illustrate its application in a prospective pilot
trial of prostate cancer AS patients by comparing the percent of biopsy-
proven prostate cancers detected by HR-DWI and S-DWI.
2. Materials and Methods
2.1. Patients
A prospective clinical trial was approved by our institutional review
board (IRB). At our center, within the ﬁrst four years of being diagnosed
with prostate cancer, men on active surveillance undergo a repeat pros-
tate biopsy every 1–2 years. Between January 2013 and January 2014, all
men scheduled to undergo a prostate biopsy for active surveillance
were offered this study (Table 1). After obtaining informed consent, a
prostate multi-parametric MRI study with both standard and high-
resolution diffusion weighted imaging was performed 2 h before their
scheduled prostate biopsy.
2.2. Biopsy and Histological Examination
All patients underwent standard ultrasound-guided transrectal
prostate biopsy on the samedayusing a side-ﬁre biopsy probe (BKMed-
ical Flex Focus 400, Peabody, MA) by a single physician (H.K. with
14 years of experience performing prostate biopsies). Ideally, the refer-
ence standard would be provided by pathology from prostatectomy.
However, the vast majority of patients with small volume tumors at
our institution are managed by active surveillance or watchful waiting,
and do not undergo prostatectomy. Therefore, to assess this technology
for the detection of small tumors, active surveillance patients were en-
rolled. A total of 12 biopsy cores were obtained from 6 different regions
of the prostate, identiﬁed as left/right and base/mid/apex. Our strategy
for correlating the 6 prostate zones between MRI and pathology has
been described (Feng et al., 2015). Brieﬂy, the prostate was divided
into equal thirds and designated anterior, mid and base. The prostateTable 1
Patient demographics







Gleason score at diagnosis
3 + 3 16
3 + 4 1
Gleason at study biopsy
Benign 5
3 + 3 9





⁎ NCCN risk category.was divided equally into left and right glands. The combination of
these two designations allowed radiologists and pathologists to identify
6 discrete prostate zones. All biopsies were reviewed by genitourinary
pathologists with expertise in prostate cancer who were blinded to
MRI ﬁndings.2.3. Imaging and Analysis
A detailed technical description of the new diffusionMRI technique has
been published (Nguyen et al., 2015). The previous work dealt with the
technical development of the novel high resolution diffusionMRI sequence
used in this study. Speciﬁcally, it primarily reported on the improvements
in image quality (susceptibility-related artifacts, ghosting, geometric distor-
tion, and spatial resolution) and ADC quantiﬁcation. The present study re-
ports results of the clinical trial, which had over 90% power to detect
discordant proportions of 0.04 and 0.40 at one-sided alpha = 0.05 and
number of biopsy-positive zones assumed to be 25.
Brieﬂy, the novel diffusion MRI technique was originally developed
for in vivo cardiac imaging and translated for prostate imaging (diffu-
sion-prepared balanced steady-state free precession approach that em-
ploys 3D multi-shot imaging). Additionally, the 3D multi-shot readout
has inherent advantages over 2D single-shot echo-planar imaging
used by S-DWI. Advantages includemarkedly reduced geometric distor-
tion, minimization of susceptibility-related artifacts, and higher achiev-
able spatial resolution. The S-DWI andHR-DWI, at two resolutions, were
integrated into a routine multiparametric (MP)-MRI protocol (S-MRI
and HR-MRI, respectively), which also included T1 and T2 weighted
(T1w and T2w) turbo spin echo sequences and dynamic contrast en-
hanced (DCE) imaging (Table 2).
Imaging was performed on a 3T MRI system (MAGNETOM Verio,
Siemens Healthcare, Erlangen, Germany) equipped with a 12-channel
pelvic phased array coil. An endorectal coil was not used. Active surveil-
lance patients were scanned 2-h before their standard 12-core biopsy to
avoid edema and hemorrhage-related artifacts induced by the biopsy.
Diffusion weighted images (b = 0, 300, 600 s/mm (Mohler et al.,
2016): 3 orthogonal directions for each non-zero b-value) were ac-
quired at two prescribed spatial resolutions: One at the typical clinical
resolution of 2.1 × 2.1 × 3.5 mm (Cohen et al., 2008) and another at a
higher spatial resolution of 0.9 × 0.9 × 3.5 mm (Cohen et al., 2008). Ap-
parent diffusion coefﬁcient (ADCi) maps were reconstructed ofﬂine
using Matlab (Mathworks, Natick, MA) assuming a monoexponential
ﬁt for each diffusion direction. A ﬁnal trace apparent diffusion coefﬁ-
cient (ADC) map was calculated (ADC = [ADCx + ADCy + ADCz]/3).Speciﬁc MR protocol parameters.
T1w T2w DCE S-DWI HR-DWI
LR HR LR HR
Acquisition readout 2D 2D 2D 2D 2D 2D 3D
TR or TRg [ms] 692 5850 3.0 4700 10,000 2000 1200
TE or TEprep [ms] 10 125 1.1 80 80 80 80
Echo Spacing [ms] – – 3.0 – – 3.0 3.5































Slice thickness [mm] 3.5 3.5 3.5 3.5 3.5 3.5 3.5
Parallel imaging [R] 2 2 2 2 2 2 2












Diffusion directions – – – 3 3 3 3
Averages 2 2 1 13 7 1 1
Bandwidth [Hz/pixel] 320 279 698 1502 762 781 801
Scan time 3:06 5:16 9:00 7:32 7:35 7:28 7:32
Fig. 1. T1w image, HR-DWI, and S-DWI of a standard spatial resolution American College
of Radiology phantom. The T1w image was acquired at higher resolution (0.5 × 0.5 mm,
Mohler et al., 2016) for visual comparison. The HR-DWI (0.9 × 0.9 mm, Mohler et al.,
2016) and S-DWI (2.1 × 2.1mm, Mohler et al., 2016) were acquired with b value =
600 s/mm (Mohler et al., 2016).
Table 3a
Status of MRI in zones with biopsy-proved prostate cancer.
Biopsy positive Standard MRI
Negative Positive Row total
High resolution
MRI
Negative 1 0 1
Positive 8 14 22
Column total 9 14
82 A.-R. Sharif-Afshar et al. / EBioMedicine 7 (2016) 80–84Imaging resolution was conﬁrmed with a standard spatial resolution
American College of Radiology phantom.
Suspicious prostatic lesions were identiﬁed and scored according to
PI-RADS (Barentsz et al., 2012) by consensus of two genitourinary radi-
ologists (RS: 20 years, LP: 5 years experience in prostate cancer MR
characterization) who were blinded to all pathology results and type
of DWI protocol (HR vs S). Positive indicators include: hypointensity
on T2w, hyperintensity on DWI, hypointensity on ADC, and early
wash-in/elevated Ktrans on DCE. Early wash-in and KTrans was calculated
using commercially available Aegis 4D Visualization software (Hologic,
San Diego, CA) for prostate. Speciﬁc morphological positive indicators
include focal or nodule-like regions of the peripheral zone (PZ) and ho-
mogenous regions of the transition zone (TZ) absent of clearly delineat-
ed margins and capsule. T1w images were used to rule out possible
confounding presence of hemorrhage and calciﬁcation. The prostate
was evaluated once using S-DWI as part of the MP-MRI protocol and
then again with the HR-DWI. All lesions with PI-RADS scores greater
than three were considered suspicious and subsequently assigned to
one of six zones to spatially correspond with the pathology report of
the 12-core biopsy.
2.4. Statistical Analysis
The results of the 12-core biopsywere considered the gold-standard
reference for the comparison of imaging methods. Study design and
data collection was planned prior to study initiation. All patients enroll-
ing in the trial had prior prostate biopsies. Any of the prostate zones
were considered positive for cancer if cancer was detected on the
study biopsy or any prior biopsy. Measures of diagnostic accuracy,
along with 95% conﬁdence intervals were calculated. A p b 0.05 was




Wehypothesized that improved image quality and resolutionwould
allow for better detection of small lesions typically found in patients un-
dergoing active surveillance. Table 1 summarizes the patient demo-
graphics for 17 patients in our pilot study. At the time of diagnosis, all
patients had Gleason 3 + 3 prostate cancer with the exception of one
patient with low-volume Gleason 3 + 4 prostate cancer. Since the
study included an MRI exam and prostate biopsy, all patients had at
least two 12-core biopsies. Some patients had 3 or more biopsies (6
had 3 biopsies, 2 had 4 biopsies, 1 had 5 biopsies and 1 had 6 biopsies).
No patient received treatment for prostate cancer, include 5α reductase
inhibitors. A patientwas considered to have cancer in a zoneof the pros-
tate if cancer was detected in that zone on any prior prostate biopsy.
3.2. Imaging and Analysis
In a previous technical report, we showed that HR-DWI had no
susceptibility-related artifacts, signiﬁcantly less geometric distortion,
and better visibility of anatomy (Nguyen et al., 2015). Enhanced spatial
resolution for HR-DWI was veriﬁed using a standard American College
of Radiology phantom (American College of Radiology, 2005). In Fig. 1,
the T1 weighted images are provided for visual comparison. HR-DWI
was able to resolve the individual holes spaced 1 mm apart but not
0.9 mm apart, indicating a resolution between 0.9 × 0.9 mm (Mohler
et al., 2016) and 1.0 × 1.0 mm (Mohler et al., 2016). S-DWI was not
able to resolve any of the grids in the ﬁgure. The resolution of S-DWI
used in our routine clinical setting is 2.1 × 2.1 mm (Mohler et al.,
2016). Therefore, HR-DWI improved resolution by a factor of 4.4 to 5.4.
HR-MRI identiﬁed tumors that S-MRI did not identify. There were 8
prostate zones from 6 unique patients where biopsy was positive andHR-MRI identiﬁed a suspicious lesion but S-MRI was completely nega-
tive (Table 3a). Fig. 2 shows representative images of MP-MRI from a
patient and it is evident that HR-DWIs have higher resolution when
compared to S-DWIs. Similar set of ﬁgures is provided for every patient
on the clinical trial. Fig. 3 shows the 6 zones of the prostate labeled with
number of patients with positive ﬁndings from biopsy, S-MRI, and HR-
MRI.3.3. Statistical Analysis
To illustrate the concordance between S-MRI and HR-MRI, Table 3A
shows a 2 × 2 table of MRI ﬁndings in prostate zones with biopsy-
detected prostate cancer (p = 0.008, exact McNemar's signiﬁcance
probability). Table 3b shows a similar table for zones where all biopsies
were negative for prostate cancer. There was a high degree of agree-
ment between S-MRI and HR-MRI when the biopsy was negative
(p = 0.500, exact McNemar's signiﬁcance probability).
The diagnostic performance of HR-MRI was higher than S-MRI
(Table 4). Prostate cancer detection in the 6 zones with biopsies served
as the reference standard. Prostate biopsies may not detect all tumors
and these test characteristics are provided as exploratory estimates.
Both S-MRI and HR-MRI were highly predictive of biopsy results
(p b 0.001 for both, Fisher's exact test), however the ROC area was sig-
niﬁcantly higher for HR-MRI when compared to S-MRI (p= 0.002, test
of equality of ROC areas). Using results from multiple 12-core biopsies
minimized sampling error inherent to 12-core prostate biopsy, yet it is
still possible that small tumor were missed by the biopsy. However,
when a biopsy is positive, there is no doubt that cancer is present.
Therefore, it is useful to consider how many of the biopsy-proven
zones had abnormal MRI. S-MRI only identiﬁed 14 of 23 biopsy-
Fig. 2. Representative T2w, S-ADC, HR-ADC, and DCE images for an active surveillance patient enrolled in this study. The arrow highlights the biopsy-proven prostate cancer.
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Fisher's exact test).4. Discussion
Prostate cancer is the most commonly diagnosed cancer in U. S men
and the second leading cause of cancer death (Siegel et al., 2014). Active
surveillance (AS) has become a standard of care for many patients diag-
nosed with clinically localized disease. There are various AS strategies
employed but most involve repeating PSA measurement and biopsy at
regular intervals. Unfortunately, prostate biopsies can be uncomfortable
and can be complicated by rectal bleeding, temporary erectile dysfunc-
tion, and even sepsis. Therefore, less invasive strategies are needed to
monitor prostate cancer on AS. Furthermore, TRUS biopsy has modest
sensitivity because up to 85% of prostate cancers are multifocal and
30% of cancers are missed with standard biopsies (Barentsz et al.,
2012; Scattoni et al., 2010; Scattoni et al., 2007; Ukimura et al., 2013).
MP-MRI is emerging as a promising tool for detection and noninva-
sive monitoring of prostate cancer (Stamatakis et al., 2013; Mullins
et al., 2013; Panebianco et al., 2014). A recent randomized study by
Panebianco et al. explored the incorporation of MP-MPI into a strategy
for prostate cancer diagnosis and reported thatMP-MRI had an accuracy
of 97% for identifying prostate cancer in men with PSA-based criteria
suggestive of prostate cancer (Panebianco et al., 2014). The authors
also reported that saturation biopsies in men with negative MRI's only
identiﬁed Gleason 6 cancers or premalignant lesions, implying that le-
sions not detected on MRI are not clinically signiﬁcant. Other groups
have reported thatMP-MRI cannot detect Gleason 3+3prostate cancer
in up to 96% of cases if the tumor volume is less than 0.5 cm (CohenFig. 3.Diagram showing the 6 prostate zones. The number of cases considered positive for
prostate cancer by prostate biopsy, standard (S) MRI, and high resolution (HR) MRI are
shown.et al., 2008) (Shukla-Dave et al., 2012; Vargas et al., 2012). However,
prostate cancer has a long natural history that can only be deﬁned
over decades. Furthermore, even higher grade cancers can escape detec-
tion on MP-MRI. A recent study by Radtke et al. compared saturation
transperineal biopsy with MRI-US fusion targeted biopsies and demon-
strated that almost 20% of Gleason 7 or greater tumors are missed if PI-
RADS 3–5 lesions are targeted (Radtke et al., 2015). Until we have stron-
ger evidence that small lesions not detected on standard MRI can be
safely ignored, even in younger patients, the goal of the research com-
munity should be to identify and characterize these lesions.
Medved et al. recently reported on using high-resolution diffusion-
weighted imaging of the prostate in 29 patients (Medved et al., 2014).
They reported that using 3.1mmvoxels (Cohen et al., 2008),when com-
pared to 6.7 mm voxels (Cohen et al., 2008), produced higher spatial
resolution but reduced signal-to-noise ratio. Our imaging technique
goes beyond simply reducing voxel size. We use multishot imaging,
and signals that persists on multiple images can be designated as true
signal and signals that come-and-go can be designated as noise. In our
imaging study, the improved resolution resulted from smaller voxels,
increased signal-to-noise ratio, and improved image quality associated
with volumetric imaging.
Our HR-DWI identiﬁed signiﬁcantly more biopsy-proven lesions
than standard diffusionMRI. The ability to visualize these lesions allows
clinicians tomonitor them serially and follow them for decades if neces-
sary. The MRI technique is made possible by a custom software written
by our team and does not require additional hardware. The protocol
used in this study added 3.5 additional minutes of scan time to produce
a 5-fold increase in spatial resolution for a total scan time of 7.5 min.
In our study, suspected lesionswere categorized using PI-RADS, ver-
sion 1 (Barentsz et al., 2012). PI-RADS, version 2 has recently been re-
leased (American College of Radiology, 2015). In this version, nearly
all cancers are identiﬁed and scored on DWI and ﬁndings on T2 images
are not factored into the ﬁnal assessment at all. DCE images are only
used to differentiate between some PI-RADS3 and 4 lesions. OurMRI se-
quence speciﬁcally improves the DWI and the ADC maps, making it po-
tentially more useful for the latest version of PI-RADS. However, until
the new PI-RADS version has been clinically validated we chose to re-
port this study using the earlier version.
An important limitation of our study is that radical prostatectomies
were not available for the majority of patients and the reference stan-
dard was provided by 12-core biopsies. However, biopsy results can
serve as a “gold standard” when the endpoint is the MRI-detection of
biopsy-proven lesions. We believe this endpoint is appropriate in a
pilot study designed to assess whether this technology should beTable 3b
Status of MRI in zones where biopsies were negative for prostate cancer.
Biopsy negative Standard MRI
Negative Positive Row total
High resolution
MRI
Negative 64 0 64
Positive 2 13 15
Column total 66 13
Table 4
Diagnostic characteristics of multiparametric MRI for predicting biopsy results (n = 90 prostate zones)
MP-MRI containing: Fisher's exact pa Sensitivityc Speciﬁcityc ROC areab PPVc NPVc
S-DWI p b 0.001 60.9% (38.5–80.3) 83.5% (73.5–90.9) 0.72 51.9% (31.9–71.3) 88.0% (78.4–94.4)
HR-DWI p b 0.001 95.7% (78.1–99.9) 81.0% (70.6–89.0) 0.88 59.5% (42.1–75.2) 98.5% (91.7–100.0)
Abbreviations:MP=multiparametric, S-DWI= standard diffusionweighted image, HR-DWI=high resolution diffusionweighted image, ROC= receiver operating characteristic, PPV=
positive predictive value, NPV= negative predictive value.
a p-Value for contingency table of biopsy and MRI results.
b p-Value comparing ROC areas = 0.002.
c 95% conﬁdence interval.
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assess HR-MRI for detecting small-volume disease. Therefore, we stud-
ied active surveillance patients and not the modern prostatectomy can-
didates who tend to have bulky disease. Also, MRI-targeted biopsies
were not used since MRI-targeting implies that the lesion was visible
on standard MRI, and we were interested in developing a technology
that could ﬁnd lesions and tumor boundaries not previously seen on
standard MRI. Another limitation is that it may not be possible to
blind radiologists to the type of DWI and that the same two radiologists
read both S-MRI andHR-MRI, leaving open the possibility that results of
oneMRI inﬂuenced reporting of the other MRI; however, we were will-
ing to accept this possibility since this effect is only likely to falsely en-
hance the reported accuracy of S-MRI and not HR-MRI.
5. Conclusion
HR-DWI provided higher spatial resolution and improved image
quality that resulted in better detection of prostate cancer inASpatients.
The ability to image small lesions is the ﬁrst step in serially monitoring
the lesions and deﬁning their long-term natural history, as well as
targeting them for biopsy, therapy and molecular characterization.
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